Cytokine News and Research

RSS

FAU scientists win $1.7 million NIH grant for research on neuroinflammation

Anxiety, depression and cognitive decline are prominent psychopathologies that together affect more than 40 million people in the United States.

20 Apr 2020

Scientists predict how the novel coronavirus spreads in a typical household

A team of scientists recently carried out a study on the transmissibility of the virus in households. Simply put, they’re trying to predict how the virus spreads in a typical family: if one person gets sick, how many others get sick? How sick? How long would it take the family to recover? These are the practical questions this study tries to answer.

17 Apr 2020

Gimsilumab trial starts in first US patient with ARDS and COVID-19

The first American patient with COVID-19 and acute respiratory distress syndrome (ARDS) has been put on the drug gimsilumab at Temple University Hospital, as part of the BREATHE clinical trial. The trial, sponsored by Roivant Sciences, will evaluate the effectiveness of intravenous gimsilumab in preventing death in patients with COVID-19 and ARDS.

16 Apr 2020

Gold-containing drug auranofin kills 95% of SARS-CoV-2 virus in 48 hours in lab conditions

A drug called auranofin, approved for the treatment of rheumatoid arthritis, effectively inhibits severe acute respiratory syndrome coronavirus (SARS-CoV-2) in laboratory conditions, as described in a new study by Georgia State University researchers.

16 Apr 2020

Specialized proteins could soak up excess cytokines in COVID-19 patients

One of the defining features of Covid-19 is the excessive immune response that can occur in severe cases. This burst of immune overreaction, also called a cytokine storm, damages the lungs and can be fatal.

16 Apr 2020

Octapharma USA supports new COVID-19 clinical trial

Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, M.D. of Sharp Memorial Hospital in San Diego, California focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure who become ventilator dependent.

16 Apr 2020

China with the world: COVID-19 experts dialogues - the 2nd talk transcript

Q: Starting from the patient admission to the hospital, what is your rule for ventilation? Do you start from HFNC, CPAP, NIV or go directly to intubation and invasive ventilation when the conventional oxygen therapy fails?

From Mindray 15 Apr 2020

How does COVID-19 attack the body?

The coronavirus disease (COVID-19) attacks the lungs, leading to pneumonia, and eventually, a cascade of serious complications. But how does COVID-19 kill? Is it the virus itself or the result of the person’s immune system response?

13 Apr 2020

Researchers discover inflammatory mechanism that contributes to autoimmune diseases

The protein STING (Stimulator of Interferon Genes) is a critical component of the body's innate immune defence system, but can also contribute to chronic autoimmune and autoinflammatory diseases.

8 Apr 2020

Purdue scientists aim to use protein power to halt tumor growth

In 2018, approximately 324,000 men died from cancer in the United States. The combination of lung cancer, prostate cancer and colorectal cancer equated to half of those deaths.

7 Apr 2020

Common protein in skin can directly activate itch-associated neurons

A commonly expressed protein in skin - periostin - can directly activate itch-associated neurons in the skin, according to new research from North Carolina State University.

7 Apr 2020

COVID-19 and renin-angiotensin system inhibitors

A new viewpoint article published in the journal JAMA Network in April 2020 deals with the use of a widely used category of cardiovascular medications in COVID-19 patients with hypertension, diabetes, and cardiovascular disease (CVD). These are the most common medical conditions that are found in COVID-19 patients and contribute disproportionately to mortality.

5 Apr 2020

Immunosuppressant shows promise in addressing COVID-19 symptoms for patients with blood cancers

A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.

5 Apr 2020

COVID-19: What the illness looks like

With increasing information about COVID-19 disease gathered first-hand, a more accurate picture of the clinical features is coming together.

2 Apr 2020

Majority of patients with mantle cell lymphoma may benefit from CAR T-cell therapy KTE-X19

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

1 Apr 2020

Putting an end to the pandemic

From the plagues of medieval Europe to the influenza pandemic of 1918, the specter of the next public health disaster has gripped the minds of scientists, captivated the imaginations of writers and vexed conspiracy theorists.

1 Apr 2020

Researchers develop a 'cardiac patch with bioink' to repair the heart

The heart is the driving force of circulating blood in the body and pumps blood to the entire body by repeating contraction and relaxation of the heart muscles continuously.

30 Mar 2020

UC Davis launches two clinical trials to evaluate treatments for COVID-19

UC Davis Health has two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.

27 Mar 2020

Model that sheds light on severe Duchenne muscular dystrophy could pave the way for new therapies

Researchers have developed an experimental model of severe Duchenne muscular dystrophy that offers insight into the disease.

26 Mar 2020

Combination produces more proliferative, enduring central memory T cells for cellular therapy

Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs them into a stronger T cell type that persists longer than its comrades, researchers at The University of Texas MD Anderson Cancer Center report in Cancer Immunology Research, a journal of the American Association for Cancer Research.

25 Mar 2020